James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Investors Gobble Up Weight Watchers Stock, But the Binge Won’t Last

Thanks to an emotional TV commercial with Oprah, Weight Watchers managed to stir traders up this week, but chatter doesn't pay the bills.

2016 Outlook: Alibaba Group Holding Ltd (BABA)

Alibaba (BABA) stock has finally shaken off its post-IPO volatility to become a real stock trading on real fundamentals. And they're pretty solid.

Why SunEdison Inc (SUNE), Energy Transfer Partners LP (ETP) and Sunstone Hotel Investors Inc (SHO) Are 3 of Today’s Worst Stocks

Sunedison (SUNE), Energy Transfer Partners (ETP) and Sunstone Hotel Investors (SHO) just couldn't win for losing during Tuesday's trading.

America’s 25 Best-Yielding Large-Cap Dividend Stocks

This list of dividend stocks should be handled with due diligence, as not every stock listed is a gem, but it is a great place to start the search for income.

Why Freeport-McMoRan Inc (FCX), Valeant Pharmaceuticals Intl Inc (VRX) and Kinder Morgan Inc (KMI) Are 3 of Today’s Worst Stocks

Owners of Freeport-McMoRan (FCX), Valeant Pharmaceuticals (VRX) and Kinder Morgan (KMI) found coal in their stockings on Monday.